Table 1.
Patient demographics and clinical characteristics.
| Total n | 193 |
| Age at first vaccine [years] mean (SD) | 47.4 (11.6) |
| Sex n (%) | |
| Female | 127 (65.8) |
| Male | 66 (34.2) |
| Ethnicity n (%) | |
| Asian | 12 (6.2) |
| Black | 7 (3.6) |
| Not recorded | 72 (37.3) |
| Other | 6 (3.1) |
| White | 96 (49.7) |
| Disease course n (%) | |
| PPMS | 16 (8.3) |
| RRMS | 147 (76.2) |
| SPMS | 30 (15.5) |
| Disease duration from onset of first symptom [years] (median, IQR) | 12.00 (7.00, 18.00) |
| EDSS (median, IQR) | 3.50 (2.00, 6.00) |
| DMT n (%) | |
| None | 12 (6.2) |
| Alemtuzumab | 14 (7.3) |
| Cladribine | 49 (25.4) |
| Dimethyl fumarate | 16 (8.3) |
| Fingolimod | 21 (10.9) |
| Natalizumab | 14 (7.3) |
| Ocrelizumab | 62 (32.1) |
| Other* | 5 (2.6) |
| Time from last treatment to first vaccine [months] mean (SD) | 13.2 (14.8) |
⁎
Other” group for DMTs composed of two pwMS on rituximab, one on ofatumumab, one on glatiramer acetate and one on interferon β−1a (Avonex).